Business Wire

Secure Access is Broken. Fyde Enterprise Fixes It.

4.11.2019 14:00:00 EET | Business Wire | Press release

Share

Fyde, the new standard for Zero Trust, today announced Fyde Enterprise, a continuous, adaptive secure access solution that mitigates risk while protecting privacy and increasing performance. As digital transformation and the cloud transform the way we work and access apps, the disappearance of the traditional corporate perimeter creates new security risks and compliance challenges that break traditional solutions like VPNs. A powerful alternative to VPNs, Fyde Enterprise works on any infrastructure, any device, and with any application on a corporate network. Distributed businesses can now modernize remote access, enforce global security and access policies, and achieve seamless connectivity without compromising productivity.

Fyde, a first-time participant at Web Summit, is a featured startup and will be speaking on Centre Stage at the Breakout startups on November 4 at 5:00 pm and November 6 at 9:15 am. Fyde is also an exhibitor in the Beta Startup Programme on Tuesday, November 5.

Zero Trust for the Modern Enterprise

The Zero Trust paradigm assumes that all access is conditional and the network is always untrusted. Every interaction with the corporate network or cloud infrastructure must be granted contextual and conditional access based on continuous evaluation of device attributes (such as critical updates, security configuration and geographic location) and user identity (such as enforcing MFA or re-authentication) to ensure the highest levels of security.

Security teams must adapt to new requirements for the cloud, employee mobile devices, and evolving access dynamics associated with contractors, partners and remote employees. Fyde’s Zero Trust approach to secure access is driven by identity-aware access control and device-trust based security policies. Fyde enables secure, reliable and fast access to authorized apps and workloads on corporate networks and cloud infrastructure from any device, network, and location. Fyde also protects user identities from account takeover attacks.

“CISOs are frustrated by the failure of their traditional secure access solutions to deliver essential visibility and control over access to corporate resources, as well as to block emerging threats,” said Sinan Eren, Fyde CEO. “Fyde is built to address the security challenges created by the evolving threat landscape, while protecting employee privacy, boosting productivity, and ensuring compliance.”

Fyde Enterprise: The Onramp to Zero Trust

Fyde Enterprise is easy to deploy, monitor and manage. Security and IAM teams can sync with their user directory for seamless onboarding and deprovisioning of users and devices, monitor and log access requests and sessions via the Fyde Enterprise management console. Fyde Enterprise includes features for today’s complex IT environments, enabling security teams to deliver:

Zero Trust on any infrastructure or platform

  • Grant minimal privileged access to authorized apps without exposing the network
  • Work on Mobile or Desktop
  • Deploy on-premises or in hybrid or public cloud
  • Continuously verify users and devices

Global Security and Access Policies

  • Create robust access policies and gain visibility into who has access, to what and from where
  • Assign role-based and attribute-based policies

Upgraded performance and privacy

  • Eliminate latency via local inspection
  • Offer self-service remediation
  • Reduce IT Costs
  • Secure the data plane: Fyde does not have visibility into data.
  • Protect employee privacy. No personal data is shared with the company.

Pricing and availability

Fyde Enterprise is available today. Fyde is sold as an annual subscription with pricing starting at $10 per user per month. Enterprise bundles are available. To try Fyde today, visit Fyde.com/sign-up

About Fyde

Fyde is the new standard for Zero Trust secure access. An increasingly decentralized world is driving digital transformation and challenging the status quo. Fyde helps organizations mitigate risks while adapting to the new nature of work and IT, powering their journey to the Zero Trust Architecture. Our innovative approach is driven by patented technology that enables secure, reliable and fast access to any on-premises, cloud or hybrid app or workload. Fyde eliminates security risks associated with traditional VPN access, while protecting user identities from account takeover attacks. To learn more about Fyde, visit Fyde.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

U.S.
Dawn van Hoegaerden
Fyde
dawn@fyde.com
@dawnvanh

Portugal
Carla Silva
Fyde
carla@fyde.com

Fyde, Inc.
425 Sherman Ave.
Suite 220
Palo Alto CA 94306
USA
+1 650 275 2835

Fyde Portugal
Rua D. João IV, 429
4000-303 Porto
Portugal
+351 919 289 288

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye